Dear All, Our colleagues in Europe have been busy! Along with yesterday's announcement about transferrable exclusivity vouchers, we also had publication of the Horizon Europe Work Programme 2026-2027. It's a really big program that includes within its Cluster 1 a trio of calls of interest to readers of this newsletter: HORIZON-HLTH-2027-01-DISEASE-08 call seeks projects developing new antibacterial and antifungal therapies (including antibody-based) targeting drug-resistant pathogens like MRSA, CRE, CRAB, CRPA, and drug-resistant Candida and Aspergillus. Projects should focus on innovative therapies with new chemical classes, targets, or modes of action (phage therapies excluded). Budget: EUR 44.2M total, with EUR 8–10M EU contribution per project. HORIZON-HLTH-2027-02-IND-02 – Portable and versatile Point-of-Care diagnostics. Developing or optimising sensitive, user-friendly devices for rapid diagnosis, including bacterial and fungal infections and non-communicable diseases. In general, priority should be given to approaches that are suitable for resource-limited settings. In case of targeting infectious diseases, priority should be given to approaches enabling the distinction between viral, bacterial or fungal infections. Budget: EUR 39.3M total, with EUR 5–7M EU contribution per project. HORIZON-HLTH-2026-01-DISEASE-03 - Advancing research on the prevention, diagnosis, and management of post-infection long-term conditions. Research on long-term conditions resulting from infections by any type of microorganism...